Investment into by Keensight Capital
Summary
Keensight Capital will invest alongside the founders, senior management, and employees.Headquartered in the United Kingdom, CatSci was formed in December 2010 from a spin-out of AstraZenecas Catalyst Screening Facility by five founders, including current co-owners Dr. Ross Burn and Dr. Simon Tyler, now CEO and COO, respectively.The company, which serves emerging, mid-sized, and large pharma companies, has six operational laboratories across two UK sites fitted with the latest high-end equipment. The company currently employs nearly 100 people, of which approximately 80% hold a PhD degree.CatSci is committed to developing economically and environmentally sustainable drug manufacturing processes that enable its global pharmaceutical customers to create affordable small molecule therapeutics to address critical public health challenges, including antimicrobial resistance, cancer, and mental health.Thanks to its differentiated positioning, excellent track record, and highly skilled scientific workforce, CatSci enjoys consistently outstanding market and customer feedback, which is reflected in its strong 30-40% per annum historical growth trajectory. Within just a few years, CatSci has won both locally and nationally recognised awards, with 2022 successes including the highly esteemed Queens Award for Enterprise: International Trade and Bionow Export of the Year Award.Keensight Capital are investing behind CatSci management to support continued growth of the core business via capability and site expansion, as well as the development of GMP capabilities and the expansion of its offering in oligonucleotide services. Their unique positioning and strong expertise in small molecule R&D, as well as their renowned high-quality scientific services and workforce, make them a critical player in the CRO ecosystem. Drawing on its expertise in the Technology and Healthcare sectors, Keensight identifies the best investment opportunities in Europe and works closely with management teams to develop and achieve their strategic vision.